DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

BACKGROUND: The current study was conducted to examine the activity of a docetaxel/oxaliplatin (DocOx) combination as second line treatment for advanced pancreatic ductal adenocarcinoma (Trial registration: NCT00690300. Registered June 2, 2008) METHODS: DocOx is a prospective, multi-center, single a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettrich, Thomas J., Perkhofer, Lukas, von Wichert, Goetz, Gress, Thomas M., Michl, Patrick, Hebart, Holger F., Büchner-Steudel, Petra, Geissler, Michael, Muche, Rainer, Danner, Bettina, Kächele, Volker, Berger, Andreas W., Güthle, Melanie, Seufferlein, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714522/
https://www.ncbi.nlm.nih.gov/pubmed/26772812
http://dx.doi.org/10.1186/s12885-016-2052-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714522/
https://www.ncbi.nlm.nih.gov/pubmed/26772812
http://dx.doi.org/10.1186/s12885-016-2052-4

Ejemplares similares